ES2968823T3 - Células estromales mesenquimales derivadas de tejido del cordón umbilical para su uso en el tratamiento de trastornos del espectro autista - Google Patents

Células estromales mesenquimales derivadas de tejido del cordón umbilical para su uso en el tratamiento de trastornos del espectro autista Download PDF

Info

Publication number
ES2968823T3
ES2968823T3 ES19781349T ES19781349T ES2968823T3 ES 2968823 T3 ES2968823 T3 ES 2968823T3 ES 19781349 T ES19781349 T ES 19781349T ES 19781349 T ES19781349 T ES 19781349T ES 2968823 T3 ES2968823 T3 ES 2968823T3
Authority
ES
Spain
Prior art keywords
years
hct
msc
months
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19781349T
Other languages
English (en)
Spanish (es)
Inventor
Joanne Kurtzberg
Geraldine Dawson
Jessica Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2968823(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2968823T3 publication Critical patent/ES2968823T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Educational Technology (AREA)
  • Psychology (AREA)
ES19781349T 2018-04-04 2019-04-04 Células estromales mesenquimales derivadas de tejido del cordón umbilical para su uso en el tratamiento de trastornos del espectro autista Active ES2968823T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (1)

Publication Number Publication Date
ES2968823T3 true ES2968823T3 (es) 2024-05-14

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19781349T Active ES2968823T3 (es) 2018-04-04 2019-04-04 Células estromales mesenquimales derivadas de tejido del cordón umbilical para su uso en el tratamiento de trastornos del espectro autista

Country Status (12)

Country Link
US (1) US12491210B2 (cg-RX-API-DMAC10.html)
EP (1) EP3773486B1 (cg-RX-API-DMAC10.html)
JP (1) JP2021520380A (cg-RX-API-DMAC10.html)
KR (1) KR20210031853A (cg-RX-API-DMAC10.html)
CN (1) CN112351785A (cg-RX-API-DMAC10.html)
AU (1) AU2019247210A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020020295A2 (cg-RX-API-DMAC10.html)
CA (1) CA3096033A1 (cg-RX-API-DMAC10.html)
ES (1) ES2968823T3 (cg-RX-API-DMAC10.html)
IL (1) IL277733B2 (cg-RX-API-DMAC10.html)
SG (1) SG11202009805PA (cg-RX-API-DMAC10.html)
WO (1) WO2019195506A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104100A1 (en) 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
ES2580136T3 (es) * 2010-12-16 2016-08-19 Autism Biotech Limited Biomarcador novedoso y usos del mismo en el diagnóstico, tratamiento de autismo
EP3429360A4 (en) * 2016-03-16 2019-08-28 Cell Medicine, Inc. MESENCHYMAL STEM CELLS WITH IMPROVED EFFICACY
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
JP7126703B2 (ja) 2016-05-24 2022-08-29 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) * 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Also Published As

Publication number Publication date
WO2019195506A1 (en) 2019-10-10
CN112351785A (zh) 2021-02-09
JP2021520380A (ja) 2021-08-19
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
SG11202009805PA (en) 2020-11-27
IL277733B2 (en) 2024-10-01
KR20210031853A (ko) 2021-03-23
EP3773486B1 (en) 2023-12-06
CA3096033A1 (en) 2019-10-10
BR112020020295A2 (pt) 2021-01-12
EP3773486A1 (en) 2021-02-17
US12491210B2 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Sagar et al. Fetal stem cell transplantation and gene therapy
Ahmad Sophien et al. Intestinal stem cells and gut microbiota therapeutics: hype or hope?
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Tai-MacArthur et al. The theoretical basis of in utero hematopoietic stem cell transplantation and its use in the treatment of blood disorders
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Khalili et al. IVF staff attitudes towards oocyte donation: a multi-centric study from Iran and Turkey
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
AU2017267809A1 (en) Amelioration and treatment of perinatal brain damage with pluripotent stem cells
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
David et al. An exploratory phase I/II trial evaluating the safety and efficacy of postnatal or pre-and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta: The BOOSTB4 Trial Protocol
Mkrtchyan et al. THE PROBLEM OF ANEMIA IN ARMENIA AMONG YOUNG CHILDREN
Fuentes et al. Short-term safety of allogeneic adipose-tissue derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomised, double-blind, placebo-controlled, single-centre, pilot clinical trial
Gupta et al. Menarche in Pediatric Patients With Crohn's Disease
Jacob et al. A Correlational Study on Knowledge and Practice of Fluid and Electrolyte Administration among Staff Nurses of Selected Hospitals at Mangaluru
Church et al. Abnormal filipin staining and phenotypic overlap between acid sphingomyelinase deficiency and Niemann-Pick C disease
Ebomoyi Neonatal screening for sickle cell disease, caveats about potential cure with innovative medical technology and the relevant evidence-based health education
Pacca Think Zebra: Promoting Awareness of PIDD
Vicario et al. Significant Publications
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases